SG11202010217YA - Methods of treating cancer - Google Patents

Methods of treating cancer

Info

Publication number
SG11202010217YA
SG11202010217YA SG11202010217YA SG11202010217YA SG11202010217YA SG 11202010217Y A SG11202010217Y A SG 11202010217YA SG 11202010217Y A SG11202010217Y A SG 11202010217YA SG 11202010217Y A SG11202010217Y A SG 11202010217YA SG 11202010217Y A SG11202010217Y A SG 11202010217YA
Authority
SG
Singapore
Prior art keywords
methods
treating cancer
cancer
treating
Prior art date
Application number
SG11202010217YA
Inventor
Alison A Armour
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of SG11202010217YA publication Critical patent/SG11202010217YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0402Organic compounds carboxylic acid carriers, fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0613Apparatus adapted for a specific treatment
    • A61N5/062Photodynamic therapy, i.e. excitation of an agent
SG11202010217YA 2018-04-17 2019-04-16 Methods of treating cancer SG11202010217YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659016P 2018-04-17 2018-04-17
US201862670442P 2018-05-11 2018-05-11
PCT/US2019/027720 WO2019204335A1 (en) 2018-04-17 2019-04-16 Methods of treating cancer

Publications (1)

Publication Number Publication Date
SG11202010217YA true SG11202010217YA (en) 2020-11-27

Family

ID=68240292

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010217YA SG11202010217YA (en) 2018-04-17 2019-04-16 Methods of treating cancer

Country Status (15)

Country Link
US (1) US20210161911A1 (en)
EP (1) EP3781215A4 (en)
JP (1) JP2021522193A (en)
KR (1) KR20210003135A (en)
CN (1) CN112368024A (en)
AU (1) AU2019255692A1 (en)
BR (1) BR112020020961A2 (en)
CA (1) CA3097381A1 (en)
CL (1) CL2020002637A1 (en)
IL (1) IL277981A (en)
MX (1) MX2020010813A (en)
PH (1) PH12020551715A1 (en)
SG (1) SG11202010217YA (en)
TW (1) TW202012000A (en)
WO (1) WO2019204335A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021025810A2 (en) 2019-06-21 2022-05-10 Provincial Health Services Authority Radiolabeled compounds targeting prostate-specific membrane antigen
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2016000137A1 (en) * 2013-10-18 2017-10-06 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer.
EP3244925A4 (en) * 2015-01-16 2018-06-06 Academia Sinica Molecular constructs with targeting and effector elements
IL237525A (en) * 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen ligand with a radioactive isotope
US10882871B2 (en) * 2016-01-10 2021-01-05 British Columbia Cancer Agency Branch 18/19F-labelled compounds which target the prostate specific membrane antigen

Also Published As

Publication number Publication date
KR20210003135A (en) 2021-01-11
AU2019255692A1 (en) 2020-11-26
TW202012000A (en) 2020-04-01
CA3097381A1 (en) 2019-10-24
IL277981A (en) 2020-11-30
US20210161911A1 (en) 2021-06-03
MX2020010813A (en) 2021-01-08
CN112368024A (en) 2021-02-12
JP2021522193A (en) 2021-08-30
PH12020551715A1 (en) 2021-07-26
EP3781215A1 (en) 2021-02-24
BR112020020961A2 (en) 2021-01-19
CL2020002637A1 (en) 2021-04-16
WO2019204335A1 (en) 2019-10-24
EP3781215A4 (en) 2021-12-29

Similar Documents

Publication Publication Date Title
IL275663A (en) Methods of treating cancer
IL269026A (en) Methods of treating tumor
HK1258098A1 (en) Methods of treating cancer
IL262342A (en) Methods of treating cancer
IL286297A (en) Methods of treating minimal residual cancer
IL264443A (en) Methods of treating prostate cancer
SG11202010793UA (en) Methods of treating cancer
EP3606531A4 (en) Methods of treating cancer
ZA201808258B (en) Methods of treating pancreatic cancer
ZA201908539B (en) Method of treatment of cancer
SG11202011117VA (en) Treatment of cancer
IL283337A (en) Methods of treating whsc1-overexpressing cancers by inhibiting setd2
EP3487999A4 (en) Methods of treating cancer
IL279591A (en) Methods of treating cancer using combination therapy
SG11202107017TA (en) Methods of treating cancer
SG11202005163PA (en) Methods of treating cancer
IL281600A (en) Methods of treating cancer
IL277981A (en) Methods of treating cancer
GB201717945D0 (en) Method for treatment of cancer
IL289811A (en) Method of treating cancer
IL269123A (en) Methods of treating cancer
IL272379A (en) Methods of treating cancer by inhibiting setd2
EP3801547A4 (en) Methods of treating cancer
EP3442555A4 (en) Methods of treating breast cancer
GB201820975D0 (en) Methods of cancer treatment